Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2014 1
2015 1
2016 1
2017 1
2018 3
2020 5
2021 7
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: doskas t. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. Alzheimers Res Ther. 2023. PMID: 36849969 Free PMC article. Clinical Trial.
Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity.
Alissafi T, Kalafati L, Lazari M, Filia A, Kloukina I, Manifava M, Lim JH, Alexaki VI, Ktistakis NT, Doskas T, Garinis GA, Chavakis T, Boumpas DT, Verginis P. Alissafi T, et al. Among authors: doskas t. Cell Metab. 2020 Oct 6;32(4):591-604.e7. doi: 10.1016/j.cmet.2020.07.001. Epub 2020 Jul 31. Cell Metab. 2020. PMID: 32738205 Free PMC article.
Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: doskas t. Alzheimers Res Ther. 2023 Apr 22;15(1):85. doi: 10.1186/s13195-023-01230-9. Alzheimers Res Ther. 2023. PMID: 37087449 Free PMC article. No abstract available.
Leukoaraiosis as a Predictor of Depression and Cognitive Impairment among Stroke Survivors: A Systematic Review.
Tziaka E, Christidi F, Tsiptsios D, Sousanidou A, Karatzetzou S, Tsiakiri A, Doskas TK, Tsamakis K, Retzepis N, Konstantinidis C, Kokkotis C, Serdari A, Aggelousis N, Vadikolias K. Tziaka E, et al. Among authors: doskas tk. Neurol Int. 2023 Feb 13;15(1):238-272. doi: 10.3390/neurolint15010016. Neurol Int. 2023. PMID: 36810471 Free PMC article. Review.
Neurocognitive impairment and social cognition in multiple sclerosis.
Doskas T, Vavougios GD, Karampetsou P, Kormas C, Synadinakis E, Stavrogianni K, Sionidou P, Serdari A, Vorvolakos T, Iliopoulos I, Vadikolias Κ. Doskas T, et al. Int J Neurosci. 2022 Dec;132(12):1229-1244. doi: 10.1080/00207454.2021.1879066. Epub 2021 Feb 25. Int J Neurosci. 2022. PMID: 33527857
26 results